ALHC Q1 Earnings Call: Membership Growth and Margin Expansion Drive Upbeat Outlook

Health insurance company Alignment Healthcare (NASDAQ: ALHC) announced better-than-expected revenue in Q1 CY2025, with sales up 47.5% year on year to $926.9 million. The company expects next quarter’s revenue to be around $957.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.05 per share was significantly above analysts’ consensus estimates.

Is now the time to buy ALHC? Find out in our full research report (it’s free).

StockStory’s Take

Alignment Healthcare began 2025 with a notable increase in membership and year-over-year revenue, propelled by its ability to manage medical costs and scale its clinical care model. CEO John Kao credited the company's approach to serving seniors, particularly through care coordination for complex and dually eligible populations, as key to its success. Kao emphasized, "Our model combines the product control and data visibility of a health plan, clinical insights of a modern technology platform, medical management expertise of a care delivery organization and member experience of a consumer-first company."

Looking forward, management raised full-year revenue and profit guidance, citing strong enrollment momentum and favorable industry dynamics. CFO Thomas Freeman highlighted the company’s operational leverage and prudent approach to medical and pharmacy cost trends. He noted that Alignment plans to channel some early-year gains into member engagement and provider partnerships, aiming to build a durable growth platform as the Medicare Advantage landscape continues to evolve.

Key Insights from Management’s Remarks

Alignment Healthcare’s management attributed the first quarter’s growth to robust membership gains and strong execution in medical cost management. The following insights emerged from their remarks:

• Membership Expansion: The company grew membership by approximately 32%, with significant gains both in California and ex-California markets. Management pointed to the scalability of its clinical model and care coordination capabilities as core drivers.
• Clinical Model Scaling: The scaling of the AVA (Alignment’s technology-enabled care model) enabled improved identification and engagement of high-risk seniors. This allowed for proactive care management, especially for dually eligible and chronically ill members, which management believes sets Alignment apart.
• Medical Cost Control: Alignment reported better-than-expected improvement in its medical benefit ratio (MBR), highlighting effective inpatient utilization management and favorable prior-year reserve releases. Management noted that these trends supported margin expansion despite rapid top-line growth.
• Strategic Technology Investment: Ongoing advances in the AVA platform are targeted at automating member experience and optimizing care outcomes. Management described a focus on efficacy and adoption rates of AVA modules, with plans to double down on those delivering measurable value.
• Leadership Transition: The company announced the transition of its long-serving CFO Thomas Freeman to a strategic advisor role, with Jim Head, a veteran healthcare finance executive, stepping in as the new CFO. Management framed this as a step to support Alignment’s next phase of growth and scaling.

Drivers of Future Performance

Management outlined a constructive outlook for 2025, driven by membership growth, operational efficiencies, and continued investments in technology and partnerships. The main themes shaping guidance are:

• Provider Collaboration Focus: Management plans to deepen long-term partnerships with providers, especially to better serve high-need seniors. These collaborations are expected to support both growth and cost control efforts.
• Technology and Data Leverage: Continued investment in the AVA platform aims to advance clinical quality and member experience, with the goal of automating and personalizing care at scale. Management believes this will further distinguish Alignment in a competitive Medicare Advantage market.
• Regulatory and Competitive Factors: Management highlighted the impact of new Medicare Advantage payment rates and risk model changes, noting that Alignment’s high plan quality ratings and efficient cost structure position it to benefit relative to some competitors. However, they acknowledged ongoing uncertainties regarding policy changes and market behavior.

Top Analyst Questions

• Ryan Daniels (William Blair): Asked about plans for expanding provider partnerships and possibly offering technology solutions externally. Management indicated that, while expansion is underway, any move into external enablement will be approached cautiously and only if it is sustainable.
• Michael Ha (Baird): Inquired about the drivers behind medical loss ratio outperformance and the potential pull-forward of earnings from Part D changes. Management clarified that Part D timing was a minor factor and that broader utilization trends and reserves management were more significant.
• Jessica Tassan (Piper Sandler): Queried about competitive changes in California and how Alignment will prepare its salesforce for increased rivalry. Management said it feels well-positioned due to partnership strengths and does not view smaller competitors as a long-term threat.
• Whit Mayo (Leerink Partners): Sought clarity on Alignment’s risk adjustment revenue processes for new members and visibility on reimbursement. Management explained its conservative approach, booking revenue based on actual payments to avoid surprises.
• Joanna Gajuk (Bank of America): Asked if further Medicare Advantage rate changes could be a headwind or opportunity for market share. Management stated that its business model is designed to adapt to either environment, emphasizing focus on cost and quality.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the scalability of Alignment’s AVA technology platform in new and existing markets, (2) the company’s ability to sustain membership growth while preserving or improving margins, and (3) further developments in provider partnerships and regulatory policy changes affecting Medicare Advantage. Execution on these priorities will be central to evaluating Alignment’s trajectory.

Alignment Healthcare currently trades at a forward EV-to-EBITDA ratio of 51.8×. Is the company at an inflection point that warrants a buy or sell? See for yourself in our free research report.

High-Quality Stocks for All Market Conditions

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.